NasdaqGS - Nasdaq Real Time Price ? USD CARGO Therapeutics, Inc. (CRGX) Follow Compare 22.22 +0.52 (+2.40%) At close: October 18 at 4:00 PM EDT 22.22 0.00 (0.00%) After hours: October 18 at 4:02 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Here's Why We're Not Too Worried About CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn Situation Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? yesterday CRGX +2.40% Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week Along with quarterly results, the clinical-stage company provided an encouraging business update. Motley Fool ? 2 months ago CRGX +2.40% CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported financial re GlobeNewswire ? 2 months ago CRGX +2.40% With 54% ownership of the shares, CARGO Therapeutics, Inc. (NASDAQ:CRGX) is heavily dominated by institutional owners Key Insights Given the large stake in the stock by institutions, CARGO Therapeutics' stock price might be vulnerable to... Simply Wall St. ? 2 months ago CRGX +2.40% CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet Ongoing Phase 1 study informed dose selection for CARGO’s currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel)1, in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced diseaseMost recent, longer-term follow-up data for Stanford Medicine’s Phase 1 presente GlobeNewswire ? 3 months ago CRGX +2.40% CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director – Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderso GlobeNewswire ? 4 months ago CRGX +2.40% Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now Many investors steer clear of limelight stocks. These ideas might already be overvalued and often aren’t the breakout stocks that can deliver significant returns. On the other hand, stocks that are undiscovered seem attractive. These are typically companies with little or no analyst coverage. Therefore, investors give minimal attention. Of course, deeper analysis on the business and valuations are needed before arriving at a conclusion. The following stocks represent companies that have good fun InvestorPlace ? 4 months ago DRS CRGX +2.40% CARGO Therapeutics to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences. TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAGina Chapman, President and Chief Executive Officer, is scheduled to participate in a virtual fireside cha GlobeNewswire ? 4 months ago CRGX +2.40% CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing – Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, tod GlobeNewswire ? 4 months ago CRGX +2.40% What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks ? 4 months ago CRGX +2.40% Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High? The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Zacks ? 4 months ago CRGX +2.40% CARGO Therapeutics Reports First Quarter 2024 Financial Results and?Provides Business Update - 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival GlobeNewswire ? 5 months ago CRGX +2.40% Is There An Opportunity With CARGO Therapeutics, Inc.'s (NASDAQ:CRGX) 21% Undervaluation? Key Insights CARGO Therapeutics' estimated fair value is US$25.75 based on 2 Stage Free Cash Flow to Equity Current... Simply Wall St. ? 5 months ago CRGX +2.40% CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors – Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) –SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company’s Boar GlobeNewswire ? 6 months ago CRGX +2.40% CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and?Provides Business Update – Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year endin GlobeNewswire ? 6 months ago CRGX +2.40% CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, Massachusetts. Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a cell therapy corporate panel di GlobeNewswire ? 7 months ago CRGX +2.40% CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California. Gina Chapman, President and Chief Executive Officer, is scheduled to present on Monday, January 8, at 9: GlobeNewswire ? 9 months ago CRGX +2.40% CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported business updates and its financial results for the third quarter ended September 30, 2023. “This year has been transformational for our company. We experienced growth across our business, including expanding our leadership team, commencing a Phase 2 clinic GlobeNewswire ? 10 months ago CRGX +2.40% 3 New Stock Listings That Can Deliver Multibagger Returns The U.S. IPO market has been relatively sluggish this year with 149 IPOs. At the same time, disappointing stories outnumbered businesses that created value. However, amidst the depression are several ideas that are poised for multibagger returns in the next few years. This column discusses three attractive IPOs during 2023 that are likely to create value backed by fundamentals. Although I have not screened any specific sector, I have used the bottom-up approach to examine noteworthy companies. L InvestorPlace ? 10 months ago KVYO CRGX +2.40% Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return CRGX S&P 500 YTD -4.02% +22.95% 1-Year +52.19% +32.94% 3-Year +52.19% +32.94%
